licensingNeurimmune turns future royalties into $425m pipeline cashSwiss biotech Neurimmune has sold part of its future royalties from its AstraZeneca-partnered experimental heart drug cliramitug to Royalty Pharma for up to $425 million, giving it fresh cash to invest … more ➔
RegulatoryOMEICOS takes repurposed drug directly into Phase 3Berlin-based OMEICOS Therapeutics can move OMT-28 directly into a pivotal Phase 3 trial in primary mitochondrial diseases after receiving supportive feedback from the U.S. Food and Drug Administration … more ➔
adobe stock photos - Michael Derrer Fuchs clinical dataNovartis drops Phase 2 radioligand therapyNovartis has discontinued development of Lu-NeoB, an experimental radioligand therapy targeting the gastrin-releasing peptide receptor, after early clinical data failed to support further developmen … more ➔
startupsImmitra Bio raises CHF 2.4M for in-vivo gene editingSwiss biotech Immitra Bio has raised CHF 2.4 million (€2.6 million) in pre-seed funding to advance an in-vivo gene editing platform initially targeting inherited blood disorders. more ➔
PhinomicsBayer Co.Lab BerlinPhinomics Brings a New Layer of Cancer Biology from the U.S. to BerlinU.S. biotech company Phinomics has established its European hub at Bayer Co.Lab Berlin, bringing a research focus that could reshape how scientists understand tumor evolution and drug resistance. The … more ➔
Samsung BiologicsCDMOSamsung Targets Swiss CDMO PolyPeptide in $1.8 Billion DealConsolidation in the contract development and manufacturing organization (CDMO) sector continues to accelerate. With a bid valued at approximately US$1.8 billion for Swiss peptide specialist PolyPeptide, … more ➔
startupsBrenus adds €11M to colorectal cancer vaccine developmentFrench biotech Brenus Pharma has raised an €11 million Series A extension to complete the Phase 1 development of its lead colorectal cancer immunotherapy and advance a second programme from its pl … more ➔
TechnologiesRNA medicine enters its second actThe COVID-19 pandemic transformed RNA technologies into one of the most visible scientific breakthroughs of the decade. mRNA vaccines demonstrated unprecedented speed of development, large-scale manufacturing … more ➔
startupsSightera raises €3M to advance AI-generated molecular gluesBelgian techbio Sightera Biosciences has raised €3 million in pre-seed financing to expand its AI drug discovery platform and advance a pipeline of small molecules in oncology and fibrosis. more ➔
clinical dataGSK setback deepens P2X3 cough drug doubtsGSK has stopped developing camlipixant for refractory chronic cough after mixed Phase 3 results, adding another setback to a P2X3 drug class that has repeatedly struggled to turn biological promise into … more ➔
adobe stock photos - Michael Derrer Fuchs 
Phinomics
Samsung Biologics
